I just got off the phone with genentech. I didn't realize there are different versions of the trial with different exclusion criteria. Unfortunately I could not get any indication when the not recruiting trials would begin. She said "probably soon". Um hmm.
http://www.clinicaltrials.gov/ct2/re...mab-MCC-DM1%22
1
Not yet recruiting
A Study of of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Condition:
Metastatic Breast Cancer Intervention:
Drug: trastuzumab-MCC-DM1
2
Recruiting
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Condition:
Metastatic Breast Cancer Intervention:
Drug: trastuzumab-MCC-DM1
3
Not yet recruiting
A Study of the Efficacy and Safety of Trastuzumab-Mcc-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease Condition:
Metastatic Breast Cancer Interventions:
Drug: trastuzumab-MCC-DM1; Drug: trastuzumab; Drug: docetaxel